חזרה לתוצאות החיפוש

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

ישראלמגייס משתתפיםPHASE2, PHASE3

מצבים רפואיים

Prostate Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • VA Greater LA Healthcare System, Los Angeles, California, United States

    Contact: Study coordinator (Janake Wijesuriya) · janake.wijesuriya@va.gov
    Contact: Principal Investigator (Gholam Reza Berenji)

  • VA Palo Alto Health Care System, Palo Alto, California, United States

    Contact: Study coordinator (Niko Del Mar) · niko.delmar@va.gov · 650-493-5000
    Contact: Principal Investigator (Minal Vasanawala)

  • Stanford University Medical Center, Palo Alto, California, United States

    Contact: Study coordinator (Mikayla Easterling) · maeast@stanford.edu
    Contact: Principal Investigator (Hong Song)

  • Sansum Clinic, Santa Barbara, California, United States

    Contact: Study coordinator (Jessica Wong) · jessica.wong2@sutterhealth.org · 805-563-5800
    Contact: Principal Investigator (Gregg Newman)

  • Saint Johns Cancer Institute, Santa Monica, California, United States

    Contact: Study coordinator (Joey Dumadag) · joey.dumadag@providence.org · 310-829-8569
    Contact: Principal Investigator (Przemyslaw Twardowski)

  • Hartford Hospital, Hartford, Connecticut, United States

    Contact: Study coordinator (Melanie Manning) · Melanie.Manning@hhchealth.org
    Contact: Principal Investigator (Andrew Salner)

  • AdventHealth, Orlando, Florida, United States

    Contact: Study coordinator (Joseph Guzzo) · joseph.guzzo@adventhealth.com · 407-303-3235
    Contact: Principal Investigator (Ravi Shridhar)

  • University Cancer and Blood Center LLC, Athens, Georgia, United States

    Contact: Study coordinator (Christen Nicole Cooper Pope) · npope@universitycancer.com · +1 706 353 2990
    Contact: Principal Investigator (Petros Nikolinakos)

  • Emory University, Atlanta, Georgia, United States

    Contact: Study coordinator (Jalpa Patel) · jalpa.r.patel@emory.edu · +1 404 778 1835
    Contact: Principal Investigator (Shahid Sattar Ahmed.)

  • Indiana University, Indianapolis, Indiana, United States

    Contact: Study coordinator (Marie Burton) · mariburt@iu.edu
    Contact: Principal Investigator (Nabil Adra)

  • University of Kansas Hospital, Kansas City, Kansas, United States

    Contact: Study coordinator (Kelsey Schwensen) · kschwensen@kumc.edu
    Contact: Principal Investigator (Xinglei Shen)

  • East Jefferson Hospital, Metairie, Louisiana, United States

    Contact: Study coordinator (Alexandra Lieberman) · alexandra.lieberman@lcmchealth.org
    Contact: Principal Investigator (Alton Oliver Sartor)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Michael Bonhomme) · michael_bonhomme@dfci.harvard.edu · 617-632-5136
    Contact: Principal Investigator (Xiao Wei.)

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Ooviya Sathiyamoorthy) · osathiya@bidmc.harvard.edu · 617-643-9923
    Contact: Principal Investigator (David J Einstein)

  • WA Uni School Of Med, St Louis, Missouri, United States

    Contact: Study coordinator (Collin Welch) · c.welch@wustl.edu · 314-454-8293
    Contact: Principal Investigator (Jeff Michalski)

  • Nebraska Cancer Specialists, Omaha, Nebraska, United States

    Contact: Study coordinator (Marlene Bridwell) · mbridwell@nebraskacancer.com · 402-334-4773
    Contact: Principal Investigator (Samuel Mehr)

  • New Jersey Urology LLC, Voorhees Township, New Jersey, United States

    Contact: Study coordinator (Gabriela Mercado) · gmercado3@nj-urology.com · 856-673-1613
    Contact: Principal Investigator (Gordon Brown)

  • Associated Med Professionals of NY, Syracuse, New York, United States

    Contact: Study coordinator (Nathan Forrest) · nathan.forrest@ampofny.com
    Contact: Principal Investigator (Steven Finkelstein)

  • Montefiore Medical Center, The Bronx, New York, United States

    Contact: Study coordinator (Tahrima Chowdhury) · tahchowdhu@montefiore.org · 718-920-6642
    Contact: Principal Investigator (Benjamin A Gartrell)

  • Central Ohio Urology Group, Gahanna, Ohio, United States

    Contact: Study coordinator (Sarah Faisal) · sarah.faisal@us-uro.com
    Contact: Principal Investigator (Benjamin Martin)

  • Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Candice Schewbel) · candice.schwebel@fccc.edu · 215-728-3075
    Contact: Principal Investigator (Matthew Zibelman)

  • Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States

    Contact: Study coordinator (Rebecca Floyd) · rebecca.floyd@startresearch.com · 843-839-1679
    Contact: Principal Investigator (Neal D Shore)

  • Texas Oncology, Dallas, Texas, United States

    Contact: Study coordinator (Marian Heaven) · marian.heaven@usoncology.com · 512-427-9467
    Contact: Principal Investigator (Michael P Herman)

  • Urology San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Sandra Davila) · sandra.davila@usa-clinicaltrials.com
    Contact: Principal Investigator (Daniel Saltzstein)

  • Utah Intermountain Medical Center, Murray, Utah, United States

    Contact: Study coordinator (Becky Arroyo) · becky.arroyo@imail.org
    Contact: Principal Investigator (David Gill)

  • Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

    Contact: Study coordinator (Brianna Woo) · bwoo@fredhutch.org
    Contact: Principal Investigator (Ruben Raychaudhuri)

  • Medical College Of Wisconsin, Milwaukee, Wisconsin, United States

    Contact: Study coordinator (Nadia Thomas) · nathomas@mcw.edu
    Contact: Principal Investigator (Deepak Kilari)

  • Novartis Investigative Site, Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site, Herston, Queensland, Australia

  • Novartis Investigative Site, Melbourne, Victoria, Australia

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Fuzhou, Fujian, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Nanjing, Jiangsu, China

  • Novartis Investigative Site, Nanjing, Jiangsu, China

  • Novartis Investigative Site, Shenyang, Liaoning, China

  • Novartis Investigative Site, Xian, Shanxi, China

  • Novartis Investigative Site, Xian, Shanxi, China

  • Novartis Investigative Site, Chengdu, Sichuan, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Guangzhou, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Tianjin, China

  • Novartis Investigative Site, Hong Kong, Hong Kong

  • Novartis Investigative Site, Beersheba, Israel

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Petah Tikva, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Novartis Investigative Site, Tel Aviv, Israel

  • Novartis Investigative Site, Kashiwa, Chiba, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Kobe, Hyōgo, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Chiba, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukushima, Japan

  • Novartis Investigative Site, Ishikawa, Japan

  • Novartis Investigative Site, Kyoto, Japan

  • Novartis Investigative Site, Petaling Jaya, Selangor, Malaysia

  • Novartis Investigative Site, Petaling Jaya, Selangor, Malaysia

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Basel, Switzerland

  • Novartis Investigative Site, Bellinzona, Switzerland

  • Novartis Investigative Site, Bern, Switzerland

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taoyuan, Taiwan

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)פנייה לחוקר (אימייל)